Pneumatosis Intestinalis Following Immune Checkpoint Inhibitor Therapy

  • Gabriel Sperling
  • , Yang Lu
  • , Malek Shatila
  • , Krishnavathana Varatharajalu
  • , Anam Khan
  • , Yinghong Wang
  • , Bryan Schneider

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

Abstract

This is a patient with anaplastic thyroid cancer who had received two cycles of lenvatinib and pembrolizumab and subsequently developed acute pneumatosis intestinalis and immune-mediated colitis. He was treated with antibiotics, oxygen, and bowel rest with symptomatic remission and resolution on repeat imaging after 7 days. The patient unfortunately expired from cardiac arrest 3 weeks after hospital discharge.

Original languageEnglish (US)
Title of host publicationChallenging Cases in Immunotherapy Related Organ Toxicities
PublisherSpringer Science+Business Media
Pages143-148
Number of pages6
ISBN (Electronic)9783031835339
ISBN (Print)9783031835322
DOIs
Publication statusPublished - 1 Jan 2025
Externally publishedYes

Keywords

  • Colitis
  • Immune checkpoint inhibitor
  • Immunotherapy
  • Pneumatosis intestinalis

Fingerprint

Dive into the research topics of 'Pneumatosis Intestinalis Following Immune Checkpoint Inhibitor Therapy'. Together they form a unique fingerprint.

Cite this